Antimicrobial Drug-Induced Thrombocytopenia: A Review of the Literature

Abstract

The incidence of drug-induced thrombocytopenia (DIT) is not well-defined, but is estimated to occur at a minimum of 10 cases per million per year. This review will focus on the potential DIT associated with specific antibacterial, antifungal, antiviral, and antiparasitic agents. Case reports, cohort studies, and clinical trials were identified using PubMed search terms for each antimicrobial along with the Boolean combiner AND to match with the following outcomes: thrombocytopenia and bleed. Thrombocytopenia was defined as a platelet count of < 100 × 10⁹/L or a decrease in platelet count of at least 50% from baseline. A majority of the data supporting antimicrobial-induced thrombocytopenia consist of case reports and small studies. However, clinicians should be vigilant in monitoring patient platelet counts, as an immune-mediated mechanism is frequently responsible for this hematologic adverse effect and is therefore unpredictable.

Keywords

antimicrobials - thrombocytopenia - coagulopathy

• References

• 1 Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008; 47 (6) 735-743
• 2 van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf 2004; 27 (Suppl. 15) 1243-1252
• 3 Prizola JL, Smythe MA, Dager WE. Drug-induced thrombocytopenia in critically ill patients. Crit Care Med 2010; 38 (6) S145-S154
• 4 Veneri D, Franchini M, Randon F, Nichele I, Pizzolo G, Ambrosetti A. Thrombocytopenias: a clinical point of view. Blood Transfus 2009; 7 (2) 75-85
• 5 Patel N, Vandewall H, Tristani L , et al. A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. J Antimicrob Chemother 2012; 67 (3) 725-735
• 6 Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357 (6) 580-587
• 7 George JN, Raskob GE, Shah SR , et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129 (11) 886-890
• 8 George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology (Am Soc Hematol Educ Program) 2009; 153-158
• 9 Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133 (2) 309-314
• 10 Christie DJ, Mullen PC, Aster RH. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest 1985; 75 (1) 310-314
• 11 Smith ME, Reid DM, Jones CE, Jordan JV, Kautz CA, Shulman NR. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest 1987; 79 (3) 912-917
• 12 Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both “drug-dependent” and “drug-specific” antibodies. Blood 2006; 108 (3) 922-927
• 13 Warkentin TE. Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. N Engl J Med 2007; 356 (9) 891-893
• 14 Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21 (4) 685-696 , vi
• 15 Bactrim DS [package insert]. Philadelphia, PA: AR Scientific, Inc.; September 2009
• 16 Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009; 7 (6) 911-918
• 17 Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M. Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med 1986; 146 (11) 2159-2164
• 18 Aitken P, Zaidi SM. Cefuroxime-induced thrombocytopenia?. Postgrad Med J 1996; 72 (854) 757-758
• 19 Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment—a retrospective analysis in 38 children with cystic fibrosis. Infection 1999; 27 (6) 355-356
• 20 Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol 1996; 95 (4) 611-612
• 21 Salamon DJ, Nusbacher J, Stroupe T, Wilson JH, Hanrahan JB. Red cell and platelet-bound IgG penicillin antibodies in a patient with thrombocytopenia. Transfusion 1984; 24 (5) 395-398
• 22 Olivera E, Lakhani P, Watanakunakorn C. Isolated severe thrombocytopenia and bleeding caused by piperacillin. Scand J Infect Dis 1992; 24 (6) 815-817
• 23 Pérez-Vázquez A, Pastor JM, Riancho JA. Immune thrombocytopenia caused by piperacillin/tazobactam. Clin Infect Dis 1998; 27 (3) 650-651
• 24 Yan MT, Chu HY, Chau T, Lin SH. Profound thrombocytopenia associated with piperacillin in a hemodialysis patient. Clin Nephrol 2009; 72 (3) 240-243
• 25 Grossjohan B, Eichler P, Greinacher A, Santoso S, Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion 2004; 44 (7) 1033-1040
• 26 Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ. Platelet-mediated bleeding caused by broad-spectrum penicillins. J Infect Dis 1987; 155 (6) 1242-1248
• 27 Bang N, Kammer R. Hematologic complications associated with B-lactam antibiotics. Rev Infect Dis 1983; 5 (Suppl. 02) S380-S393
• 28 Sakata H, Kakehashi H, Fujita K, Yoshioka H. Effects of aztreonam on fecal flora and on vitamin K metabolism. Antimicrob Agents Chemother 1990; 34 (6) 1045-1047
• 29 Agnelli G, Del Favero A, Parise P , et al. Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?. Antimicrob Agents Chemother 1986; 29 (6) 1108-1109
• 30 Zyvox [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Company; 2009
• 31 Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34 (5) 695-698
• 32 Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37 (12) 1609-1616
• 33 Minson Q, Gentry CA. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. Pharmacotherapy 2010; 30 (9) 895-903
• 34 Hogan HL, Hachem RY, Neuhauser M, Raad II, Coyle E. Clinical experience of linezolid in bone marrow transplantation patients. J Pharm Pract 2010; 23 (4) 352-357
• 35 Wu VC, Wang YT, Wang CY , et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42 (1) 66-72
• 36 Matsumoto K, Takeshita A, Ikawa K , et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010; 36 (2) 179-181
• 37 Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54 (4) 832-835
• 38 Plachouras D, Giannitsioti E, Athanassia S , et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 2006; 43 (9) e89-e91
• 39 Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003; 37 (4) 517-520
• 40 Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340 (3) 227-228
• 41 Pascoalinho D, Vilas MJ, Coelho L, Moreira P. Linezolid-related immune-mediated severe thrombocytopenia. Int J Antimicrob Agents 2011; 37 (1) 88-89
• 42 Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38 (8) 1058-1064
• 43 Shah RA, Musthaq A, Khardori N. Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report. J Med Case Reports 2009; 3: 7290
• 44 Govindarajan R, Baxter D, Wilson C, Zent C. Vancomycin-induced thrombocytopenia. Am J Hematol 1999; 62 (2) 122-123
• 45 Lee JH, Kim DS, Lee HS, Choi SI, Cho YG. A case of vancomycin-induced thrombocytopenia. Korean J Hematol 2009; 44 (4) 294-297
• 46 Kenney B, Tormey CA. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets 2008; 19 (5) 379-383
• 47 O'Donnell E, Shepherd C, Neff A. Immune thrombocytopenia from vancomycin in orthopedic cement. Am J Hematol 2007; 82 (12) 1122
• 48 Von Drygalski A, Curtis BR, Bougie DW , et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007; 356 (9) 904-910
• 49 Myers MW, Jick H. Hospitalization for serious blood and skin disorders following use of co-trimoxazole. Br J Clin Pharmacol 1997; 43 (4) 446-448
• 50 Yamreudeewong W, Fosnocht BJ, Weixelman JM. Severe thrombocytopenia possibly associated with TMP/SMX therapy. Ann Pharmacother 2002; 36 (1) 78-82
• 51 Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4 (2) 426-428
• 52 Kaufman DW, Kelly JP, Johannes CB , et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82 (9) 2714-2718
• 53 Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998; 54 (9-10) 701-706
• 54 Hagen MD, White RD. Thrombocytopenia secondary to trimethoprim-sulfamethoxazole. South Med J 1983; 76 (4) 503
• 55 Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994; 84 (1) 176-183
• 56 Kiefel V, Santoso S, Schmidt S, Salama A, Mueller-Eckhardt C. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia. Transfusion 1987; 27 (3) 262-265
• 57 Herrington A, Mahmood A, Berger R. Treatment options in sulfamethoxazole-trimethoprim-induced thrombocytopenic purpura. South Med J 1994; 87 (9) 948-950
• 58 Martínez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 1999; 78 (6) 361-369
• 59 Covic A, Goldsmith DJ, Segall L , et al. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant 1998; 13 (4) 924-929
• 60 Blajchman MA, Lowry RC, Pettit JE, Stradling P. Rifampicin-induced immune thrombocytopenia. BMJ 1970; 3 (5713) 24-26
• 61 Kakaiya RM, Dehertogh D, Walker FJ, Cummings E, Uzdejczyk M. Rifampin-induced immune thrombocytopenia. A case report. Vox Sang 1989; 57 (3) 185-187
• 62 Mori M, Izawa K, Fujikawa T , et al. A case of acute and severe thrombocytopenia due to readministration of rifampicin. J Infect Chemother 2011; 17 (2) 288-290
• 63 Martínez E, Muñiz E, Domingo P. Evidence implicating rifampin-independent antiplatelet antibodies in the pathogenesis of rifampin-induced immune thrombocytopenia. Clin Infect Dis 1994; 19 (2) 351-353
• 64 Burgess JK, Lopez JA, Gaudry LE, Chong BH. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies. Blood 2000; 95 (6) 1988-1992
• 65 Pereira J, Hidalgo P, Ocqueteau M , et al. Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia. Br J Haematol 2000; 110 (4) 907-910
• 66 Mehta YS, Jijina FF, Badakere SS, Pathare AV, Mohanty D. Rifampicin-induced immune thrombocytopenia. Tuber Lung Dis 1996; 77 (6) 558-562
• 67 Hadfield JW. Rifampicin-induced thrombocytopenia. Postgrad Med J 1980; 56 (651) 59-60
• 68 Pujet JC, Homberg JC, Decroix G. Sensitivity to rifampicin: incidence, mechanism, and prevention. BMJ 1974; 2 (5916) 415-418
• 69 Levaquin [package insert]. Austin, TX: Hospira, Inc.; August 2009
• 70 Cipro [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals; November 2011
• 71 Avelox [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals; October 2011
• 72 Salloum R, Liu CY, Weise AM. Possible case of levofloxacin-induced thrombocytopenia. Am J Health Syst Pharm 2011; 68 (1) 43-46
• 73 Cheah CY, De Keulenaer B, Leahy MF. Fluoroquinolone-induced immune thrombocytopenia: a report and review. Intern Med J 2009; 39 (9) 619-623
• 74 Chan CS, Tuazon CU, Lessin LS. Amphotericin-B-induced thrombocytopenia. Ann Intern Med 1982; 96 (3) 332-333
• 75 Shigemi A, Matsumoto K, Ikawa K , et al. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia. Int J Antimicrob Agents 2011; 38 (5) 417-420
• 76 Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362 (6) 504-512
• 77 Kulpa J, Zaroulis CG, Good RA, Kutti J. Altered platelet function and circulation induced by amphotericin B in leukemic patients after platelet transfusion. Transfusion 1981; 21 (1) 74-76
• 78 Hussein MA, Fletcher R, Long TJ, Zuccaro K, Bolwell BJ, Hoeltge A. Transfusing platelets 2h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival. Transfus Med 1998; 8 (1) 43-47
• 79 Slichter SJ, Davis K, Enright H , et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105 (10) 4106-4114
• 80 Sloand EM, Kumar P, Yu M, Klein HG. Effect of amphotericin B and fluconazole on platelet membrane glycoproteins. Transfusion 1994; 34 (5) 415-420
• 81 Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 1977; 11 (2) 244-247
• 82 Meyer R, Axelrod JL. Fatal aplastic anemia resulting from flucytosine. JAMA 1974; 228 (12) 1573
• 83 Stamm AM, Diasio RB, Dismukes WE , et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83 (2) 236-242
• 84 Shindo K, Mizuno T, Matsumoto Y , et al. Granulocytopenia and thrombocytopenia associated with combination therapy of amphotericin B and low-dose flucytosine in a patient with cryptococcal meningitis. DICP 1989; 23 (9) 672-674
• 85 Diasio RB, Lakings DE, Bennett JE. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother 1978; 14 (6) 903-908
• 86 Harris BE, Manning BW, Federle TW, Diasio RB. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother 1986; 29 (1) 44-48
• 87 Mercurio MG, Elewski BE. Thrombocytopenia caused by fluconazole therapy. J Am Acad Dermatol 1995; 32 (3) 525-526
• 88 Agarwal A, Sakhuja V, Chugh KS. Fluconazole-induced thrombocytopenia. Ann Intern Med 1990; 113 (11) 899
• 89 Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85 (4) 481-489
• 90 Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990; 113 (3) 183-187
• 91 Costello C. Haematological abnormalities in human immunodeficiency virus (HIV) disease. J Clin Pathol 1988; 41 (7) 711-715
• 92 Cancidas [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2010
• 93 Lynch J, Wong-Beringer A. Caspofungin: a potential cause of reversible severe thrombocytopenia. Pharmacotherapy 2004; 24 (10) 1408-1411
• 94 Eraxis [package insert]. New York, NY: Pfizer; 2010
• 95 Mycamine [package insert]. Deerfield, IL: Astellas Pharma US, Inc; 2011
• 96 Nazzal M, Safi F, Arma F, Nazzal M, Muzaffar M, Assaly R. Micafungin-induced thrombotic thrombocytopenic purpura: a case report and review of the literature. Am J Ther 2011; 18 (6) e258-e260
• 97 Paya C, Humar A, Dominguez E , et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 (4) 611-620
• 98 Danziger-Isakov L, Mark Baillie G. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant 2009; 23 (3) 295-304
• 99 Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011; 86 (10) 1009-1026
• 100 Raisch DW, Straight TM, Holodniy M. Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. Pharmacotherapy 2009; 29 (8) 988-992
• 101 Brinker AD, Beitz J. Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. Am J Hematol 2002; 70 (4) 313-317
• 102 New risk management plan and patient medication guide for Qualaquin (quinine sulfate) [drug safety communication]. Rockville, MD: U.S. Food and Drug Administration; July 28, 2010 http://www.fda.gov.ezproxy.galter.northwestern.edu/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218202.htm . Accessed February 15, 2012
• 103 Perdomo J, Yan F, Ahmadi Z, Jiang XM, Stocker R, Chong BH. Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. Blood 2011; 117 (22) 5975-5986
• 104 Freiman JP. Fatal quinine-induced thrombocytopenia. Ann Intern Med 1990; 112 (4) 308-309
• 105 Kunicki TJ, Russell N, Nurden AT, Aster RH, Caen JP. Further studies of the human platelet receptor for quinine- and quinine-dependent antibodies. J Immunol 1981; 126 (2) 398-402
• 106 Yildiz BO, Haznedaroğlu IC, Cöplü L. Albendazole-induced amegakaryocytic thrombocytopenic purpura. Ann Pharmacother 1998; 32 (7-8) 842
• 107 Fernández FJ, Rodríguez-Vidigal FF, Ledesma V, Cabanillas Y, Vagace JM. Aplastic anemia during treatment with albendazole. Am J Hematol 1996; 53 (1) 53-54
• 108 Albenza [package insert]. Mississauga, Ontario, Canada: GlaxoSmithKline; 2011
• 109 Kempin SJ, Jackson CW, Edwards CC. In vitro inhibition of platelet function and coagulation by pentamidine isethionate. Antimicrob Agents Chemother 1977; 12 (4) 451-454
• 110 Nebupent [package insert]. Schaumburg, IL: APP Pharmaceuticals, LLC; December 2010
• 111 Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988; 109 (4) 280-287
• 112 Milder JE, Walzer PD, Powell Jr RD. Treatment of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole and pentamidine: efficacy and toxicity. South Med J 1979; 72 (12) 1626-1628
• 113 Christie DJ, Sauro SC, Cavanaugh AL, Kaplan ME. Severe thrombocytopenia in an acquired immunodeficiency syndrome patient associated with pentamidine-dependent antibodies specific for glycoprotein IIb/IIIa. Blood 1993; 82 (10) 3075-3080
• 114 Reese JA, Li X, Hauben M , et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010; 116 (12) 2127-2133
• 115 Rabinovitz M, Pitlik SD, Halevy J, Rosenfeld JB. Ethambutol-induced thrombocytopenia. Chest 1982; 81 (6) 765-766
• 116 Kant S, Verma SK, Gupta V, Anand SC, Prasad R. Pyrazinamide induced thrombocytopenia. Indian J Pharmacol 2010; 42 (2) 108-109